Schroder Investment Management Group Has $39.61 Million Stock Position in Exact Sciences Co. (NASDAQ:EXAS)

Schroder Investment Management Group lessened its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 52.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 704,780 shares of the medical research company’s stock after selling 765,937 shares during the period. Schroder Investment Management Group’s holdings in Exact Sciences were worth $39,609,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of EXAS. Asset Planning Inc bought a new position in Exact Sciences during the 4th quarter worth $40,000. Modus Advisors LLC acquired a new stake in shares of Exact Sciences in the fourth quarter valued at about $43,000. AlphaQuest LLC raised its position in shares of Exact Sciences by 22,825.0% during the fourth quarter. AlphaQuest LLC now owns 917 shares of the medical research company’s stock worth $52,000 after acquiring an additional 913 shares during the last quarter. SBI Securities Co. Ltd. acquired a new position in shares of Exact Sciences in the fourth quarter worth approximately $66,000. Finally, Kieckhefer Group LLC bought a new stake in Exact Sciences in the fourth quarter valued at approximately $188,000. Institutional investors own 88.82% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Benchmark restated a “buy” rating and set a $65.00 price target on shares of Exact Sciences in a report on Monday, January 13th. Guggenheim set a $60.00 target price on shares of Exact Sciences and gave the stock a “buy” rating in a research note on Friday. Piper Sandler dropped their target price on shares of Exact Sciences from $75.00 to $70.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Bank of America decreased their price target on Exact Sciences from $72.00 to $65.00 and set a “buy” rating for the company in a report on Thursday, February 20th. Finally, William Blair reissued an “outperform” rating on shares of Exact Sciences in a research note on Thursday, February 20th. Two research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $70.26.

Exact Sciences Stock Up 0.4 %

Exact Sciences stock opened at $43.45 on Wednesday. The firm has a market capitalization of $8.07 billion, a price-to-earnings ratio of -7.80 and a beta of 1.25. The firm’s fifty day moving average price is $49.33 and its two-hundred day moving average price is $57.43. Exact Sciences Co. has a 1-year low of $40.62 and a 1-year high of $79.62. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.23. The business had revenue of $713.42 million for the quarter, compared to analysts’ expectations of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. On average, equities research analysts predict that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.